Our new "Eyes on the End" series kicks off with an up-close-and-personal glimpse at what's driving the HIV epidemic in the Atlanta metropolitan area.
"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."
Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.
But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.
In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.
"At this year's International AIDS Conference ... we witnessed several pivotal developments in the global HIV response," Sean Hosein writes. "We also saw some setbacks in our efforts to prevent infections and improve the lives of people living with H...
An HIV vaccine has remained elusive. But a set of new strategies in trials around the world may finally turn that around. Rod McCullom reports.
On May 18, the annual observance of HIV Vaccine Awareness Day will draw public attention to the pursuit and promise of safe and effective HIV vaccines....
"A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified -- cost shouldn't be one of them," write James Krellenstein and Jeremiah Johnson.
The hope for a cure is at an all time high, but the science is still fragile.